Home › Funds › Lion Point Capital, LP › MIST
Lion Point Capital, LP position in MIST
MILESTONE PHARMACEUTICALS IN · Health Care
Lion Point Capital, LP reported holding 820,000 shares of MIST (MILESTONE PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$1.1M, representing 5.26% of its reported portfolio and ranking #7 among its reported holdings. Lion Point Capital, LP has disclosed MIST holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Lion Point Capital, LP's MIST position evolved
Lion Point Capital, LP first disclosed a stake in MIST in Q3 2023 at 450,207 shares (US$1.4M). The position peaked in Q1 2024 at 2,300,207 shares, worth US$4.1M. Across 12 filings, Lion Point Capital, LP increased the stake 6 time(s), trimmed it 3 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 820,000 shares valued at US$1.1M. Notable position changes include a 267% increase in Q4 2023 (shares rose 7% over the following quarter), a 39% increase in Q1 2024 (shares fell 26% over the following quarter), a 47% trim in Q1 2025 (shares rose 142% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 450.21K | $1.40M | New |
| Q4 2023 | 1.65M | $2.76M | Add |
| Q1 2024 | 2.30M | $4.12M | Add |
| Q2 2024 | 2.34M | $3.09M | Add |
| Q3 2024 | 1.65M | $2.51M | Reduce |
| Q4 2024 | 1.03M | $2.42M | Reduce |
| Q1 2025 | 548.81K | $439.10K | Reduce |
| Q2 2025 | 548.81K | $1.06M | Hold |
| Q3 2025 | 658.55K | $1.32M | Add |
| Q4 2025 | 755.00K | $1.53M | Add |
| Q1 2026 | 820.00K | $975.80K | Add |
| Q2 2026 | 820.00K | $1.10M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MIST and 13F data
MIST (MILESTONE PHARMACEUTICALS IN) is a Health Care company. 30 other funds we track also report a position in MIST — the largest reported positions include Propel Bio Management, LLC (US$10.0M), Pavaki Capital Management LLC (US$8.1M), Simplify Asset Management Inc. (US$4.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MIST
- Propel Bio Management, LLC 7.43M sh · $9.96M · Q2 2026
- Pavaki Capital Management LLC 9.34M sh · $8.08M · Q3 2026
- Simplify Asset Management Inc. 3.35M sh · $4.49M · Q2 2026
- Kalehua Capital Management LLC 1.27M sh · $1.70M · Q2 2026
More on Lion Point Capital, LP
FAQ
How long has Lion Point Capital, LP held MIST?
Lion Point Capital, LP has disclosed MIST holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Lion Point Capital, LP's current position in MIST?
As of Q2 2026, Lion Point Capital, LP holds 820.00K shares of MIST (MILESTONE PHARMACEUTICALS IN), valued at $1.10M, representing 5.26% of its reported portfolio and ranking #7.
Has Lion Point Capital, LP been buying or selling MIST?
In the latest 13F filing (Q2 2026), Lion Point Capital, LP held unchanged its position in MIST. The position peaked in Q1 2024 at 2.30M shares.
Which other funds hold MIST?
Other major institutional holders of MIST include Propel Bio Management, LLC, Pavaki Capital Management LLC, Simplify Asset Management Inc., among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.